CNA Development LLC, an affiliate of Janssen Pharmaceuticals, has filed an IND for an antibody discovered using Ligand’s OmniAb technology triggering a $1 million milestone payment to Ligand. “This milestone represents an important step in the development process and is the second IND filed with the FDA for an antibody discovered with the OmniAb technology,” said John Higgins, chief executive officer of Ligand. “Ligand acquired the OmniAb technology platform in January of 2016 and has since ...